Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3, which is a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation. The company reported that its BRAFTOVI® regimen with additional chemotherapy backbone managed to increase response rates for certain ...